Rua Bioscience, a medicinal cannabis company, has reported a significant increase in revenue and a narrower loss for the financial year ended June 30, 2025.
Revenue from customers reached $1.5 million, compared to $85,837 in the previous year.
Total revenue and other income also surged to $1.9m, up from $321,678.
The company's loss before tax decreased to $3.5m, from $13.7m in FY24.
Rua attributed its strong revenue growth to its export-led strategy and successful execution in key international markets, including Germany, Australia, Aotearoa New Zealand, the United Kingdom, and Czechia.
The company said it has established a strong presence in high-growth markets and secured partnerships for long-term revenue growth.
Rua's focus for the future will be on accelerating revenue streams in these key markets.
See more
